Spyre Therapeutics (SYRE) Receivables - Net (2016 - 2024)
Spyre Therapeutics (SYRE) has disclosed Receivables - Net for 5 consecutive years, with $5.9 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Receivables - Net changed N/A year-over-year to $5.9 million, compared with a TTM value of $5.9 million through Dec 2024, changed N/A, and an annual FY2024 reading of $5.9 million, changed N/A over the prior year.
- Receivables - Net was $5.9 million for Q4 2024 at Spyre Therapeutics, roughly flat from $5.9 million in the prior quarter.
- Across five years, Receivables - Net topped out at $21.5 million in Q1 2021 and bottomed at $5.9 million in Q2 2024.